ClinicalTrials.gg
RecruitingNCT05667506Updated Aug 12, 2025

A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

A Phase 1/2 interventional study of single dose of CNCT19 in B-cell Acute Lymphoblastic Leukemia, sponsored by Juventas Cell Therapy Ltd.. Recruiting at 9 sites in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Juventas Cell Therapy Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
47
Allocation
Not applicable
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 102 studies in Burkitt Lymphoma with a site in China — 58 open to participants now, 62 under way, 4 of them phase 3. Burkitt Lymphoma · China.

Planned enrollment
26th of 100
47 · median 24
Started
2023
with 3 others
Phase 1/2
21 of 102
9 open now
Primary completion
2025-05
later than 10 of 61 live
Registered
49th of 102
by date

Among the 102 studies in Burkitt Lymphoma with a site in China, this one is the 26th largest by planned enrollment of the 100 interventional ones that give a count, is one of 4 that started in 2023, is one of 21 in phase 1/2, reaches primary completion later than 10 of the 61 other live ones, and was the 49th registered.

Burkitt Lymphoma

977 studies on the registry are indexed under Burkitt Lymphoma; 160 are open to participants now.

Browse Burkitt Lymphoma studies →

Open to participants now

58 of the 102 studies in Burkitt Lymphoma with a site in China are open now. Recruiting first, the newest first:

53 more — sign in →

All 58 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 130 Burkitt Lymphoma studies recruiting now, 40 (31%) set no upper age limit and 77 (59%) stop at 75 or younger; 75 take children under 18; 2 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Burkitt Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).

Read the detailed description

This trial is a multi-center, open label, single-arm, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 in Children and Adolescent(aged 3\~18 years old) patients (pediatric) with r/r B-cell ALL.

The phase Ib part of the trial is to evaluate the safety, optimal dose of CNCT19, Pharmacokinetics/Pharmacodynamics(PK/PD)and preliminary efficacy in the treatment of Children and Adolescent patients with r/r B-cell ALL.

The phase II part of the trial is to evaluate the efficacy and safety of CNCT19 in in the treatment of Children and Adolescent patients with r/r B-cell ALL.

The study includes screening, pre-treatment (Cell Product manufacture \& lymphodepletion), CNCT19 infusion , safety and efficacy follow-up, and survival follow-up. All subjects who have received CNCT19 infusion will be followed for up to 2 years.

03

Conditions studied

  • B-cell Acute Lymphoblastic Leukemia

Browse trials for

Keywords

  • CNCT19
  • Cluster of differentiation antigen 19(CD19)
  • CD19-directed CAR-T cells
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Signed written prior to any study procedures (patient and/or parent or legal guardian)
  2. Age 3 to 18. Weight ≥10kg
  3. acute lymphoblastic leukemia (ALL).
  4. Documentation of CD19 tumor expression demonstrated in bone marrow or peripheral blood within 3 months before screening.
  5. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening.
  6. (age ≥ 16 years) performance status ≥ 70 or Lansky (age \< 16 years) performance status ≥ 50 at screening
  7. Organ function requirements: All patients must have adequate renal and liver functions

Key Exclusion Criteria:

  1. Active Central Nervous System (CNS) involvement by .
  2. Isolated extra-medullary disease relapse.
  3. Patients with Burkitt's lymphoma/leukemia, mixed phenotypic acute leukemia and Chronic Myelogenous Leukemia in Blast Crisis
  4. History of concomitant genetic syndrome
  5. Patients with acute (GVHD) or moderate-to-severe chronic GVHD within 4 weeks before screening.
  6. Active systemic disease
  7. Known infection with (HIV) or chronic infection with virus (HbsAg positive) or virus (anti-HCV positive).
  8. Patients with active infections at screening.
  9. Patients who received specified chemotherapy before CNCT19 infusion
  10. Radiotherapy before CNCT19 infusion:

    Non-CNS site of radiation completed \< 4 weeks prior to CNCT19 Infusion; CNS directed radiation completed \< 8 weeks prior to CNCT19 infusion.

  11. Donor lymphocyte infusion (DLI) must be stopped > 6 week prior to CNCT19 infusion.
  12. Has had treatment with any prior CAR-T therapy.
  13. \< 3 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
47 participants (estimated)

Study arms

  • Experimental
    Single dose of CNCT19

    A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by investigational treatment, CNCT19.

    Biological: single dose of CNCT19

Interventions

  • Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously. Lymphodepletion treatment: Drugs:Fludarabine Drugs: Cyclophosphamide

06

What researchers measure

Primary outcomes

  1. Overall Remission Rate (ORR)

    ORR is defined as Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi) per NCCN classification, as determined by Independent Review Committee (IRC)

    Time frame: within 3 months

Secondary outcomes

  1. Overall complete Remission Rate (ORR) with minimal residual disease (MRD) negativity as determined by IRC and Investigators

    MRD negativity status as determined using flow cytometry

    Time frame: within 3 months

  2. Overall Remission Rate (ORR) as determined by IRC and Investigators

    The Investigators' evaluation results of ORR will be utilized in the sensitivity analysis

    Time frame: at the end of month 3

  3. Overall Remission Rate (ORR) with minimal residual disease (MRD) negativity as determined by IRC and Investigators

    MRD negativity as determined using flow cytometry

    Time frame: at the end of Month 3

  4. Best overall response (BOR)

    The proportion of patients who have achieved the best response (CR or CRi) after CNCT19 treatment

    Time frame: up to 2 years

  5. Duration of remission (DOR)

    DOR is defined as the time between their first complete response per independent review to relapse or any death in the absence of documented relapse

    Time frame: to data cutoff date

  6. Allogeneic Stem Cell Transplant (Allo-SCT) rate

    The proportion of patients who have received Allo-SCT after CNCT19 treatment

    Time frame: First infusion date of CNCT19 to data cutoff date(up to 2 years)

  7. Relapse Free Survival (RFS)

    RFS is defined as the time from the CNCT19 infusion date to the date of disease relapse or death from any cause.

    Time frame: 2 years

  8. Overall survival (OS)

    OS is defined as the time from the CNCT19 Cell Injection infusion to the date of death from any cause

    Time frame: 2 years

  9. Treatment-Emergent Adverse Events

    Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAE) and Severity of TEAE

    Time frame: up to 2 years

  10. Percentage of Participants Experiencing Clinically Significant Laboratory Abnormalities

    Clinically significant laboratory abnormalities were defined as per investigator's discretion

    Time frame: From CNCT19 infusion to date of data cutoff (maximum: 2 years)

  11. In vivo cellular Pharmacokinetic (PK) profile of CNCT19

    To characterize the concentration of CAR-T cell in peripheral blood, bone marrow and cerebral spinal fluid (CSF, if available)by Flow Cytometry and quantitative polymerase chain reaction(qPCR).

    Time frame: Up to 3 months(BM sample); Up to 2 years(Blood sample)

  12. Pharmacokinetic (PK)- Cmax of CNCT19

    Maximum detected concentration of CNCT19 in peripheral blood

    Time frame: Up to 2 years

  13. Pharmacokinetic (PK)- Tmax of CNCT19.

    Time to maximum concentration of CNCT19 in peripheral blood

    Time frame: Up to 2 years

  14. Pharmacokinetic (PK)- AUC of CNCT19.

    Area under the concentration (AUC) vs time curve of CNCT19 in peripheral blood

    Time frame: Up to 2 years

  15. Concentration of Cytokines in Serum

    Collected as pharmacodynamic data, including IL-6 at least

    Time frame: 28 days

  16. Percentage of participants with anti-CNCT19 antibodies in serum

    To characterize prevalence and incidence of humoral immunogenicity to CNCT19

    Time frame: 2 years

07

Study locations

6 of 9 sites recruiting
  • The Second Hospital of Anhui Medical University
    Hefei, Anhui, China
    Not yet recruiting
    • Ningling Wang, Dr. · Contact
  • Children's Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality, China
    Recruiting
    • Xianmin Guan, Dr. · Contact
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong, China
    Recruiting
    • Yingyi He, Dr. · Contact
  • Nanfang Hospital
    Guangzhou, Guangdong, China
    Not yet recruiting
    • Hongsheng Zhou, Dr. · Contact
  • Union Hospital Tongji Medical College Huazhong University of Science of Technology
    Wuhan, Hubei, China
    Not yet recruiting
    • Heng Mei, Dr. · Contact
  • Children's Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
    Recruiting
    • Yongjun Fang, Dr. · Contact
  • The Affiliated Hospital of Xuzhou Medical University
    Xuzhou, Jiangsu, China
    Recruiting
    • Kailin Xu, Dr. · Contact
  • The First Affilicated Hospital of Nanchang University
    Nanchang, Jiangxi, China
    Recruiting
    • Fei Li, Dr. · Contact
  • Institute of Hematology & Blood Diseases Hospital
    Tianjin, Tianjin Municipality, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Currently the investigators have no plan of interim anaylsis, the investigators don't plan to share individual participant data(IPD) during the trial on-going.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2023 to primary completion in May 2025, 27 months.

Of 50 phase 1/2 interventional studies under Burkitt Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 114. This study's 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 28, 2022
StartActual
Feb 7, 2023
Primary completionActual
May 30, 2025
CompletionEst.
May 30, 2027
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05667506
Lead sponsor
Juventas Cell Therapy Ltd.
Responsible party
Sponsor
First posted
Dec 28, 2022
Start date
Feb 7, 2023
Primary completion
May 30, 2025
Completion
May 30, 2027 (estimated)
Last update
Aug 12, 2025

Study contacts

Hui Ding
Contact
dinghui@juventas.cn
+86-010-65960098
Xiaofan Zhu, M.D
principal investigator · Institute of Hematology & Blood Diseases Hospital, China

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inaticabtagene autoleucel

Start the discussion